Auranofin Market by Form, Indication - Global Forecast 2024-2030

List of Tables

[191 Pages Report] The Auranofin Market size was estimated at USD 209.20 million in 2023 and expected to reach USD 218.99 million in 2024, at a CAGR 4.81% to reach USD 290.85 million by 2030.

Auranofin is a gold-containing, orally administered compound classified as a disease-modifying antirheumatic drug (DMARD). It was specifically designed for the treatment of rheumatoid arthritis, a chronic autoimmune situation characterized by inflammation and pain in the joints. Auranofin works by modulating the immune system to decrease inflammation and slows the progression of the disease. Additionally, its immunoregulatory properties have spurred research into its potential efficacy against other autoimmune disorders and certain types of cancer. Despite its therapeutic benefits, its use is often carefully weighed against potential side effects, including renal and hepatic impairment, necessitating regular monitoring of patients under treatment. Auranofin represents a unique approach to managing autoimmune diseases, emphasizing the importance of balancing efficacy with safety in chronic disease management. The rising prevalence of rheumatoid arthritis and the need for alternative treatments amidst growing drug resistance are fundamental growth drivers. Advances in research demonstrating auranofin's efficacy against certain cancers and parasites further expand its market. Moreover, governmental and non-governmental funding for chronic diseases and cancer research plays a significant role in market expansion. However, side effects associated with auranofin, such as gastrointestinal issues and dermatological reactions, limit its acceptability among some patients. Regulatory hurdles and the high cost of clinical trials for new applications are significant challenges. The exploration of Auranofin's application in oncology and parasitology presents significant growth opportunities. Its potential effectiveness against drug-resistant cancers and parasites could open new market segments. Additionally, partnerships between pharmaceutical companies and research institutions aimed at expanding Auranofin's applications could spur further growth.

KEY MARKET STATISTICS
Base Year [2023]	USD 209.20 million
Estimated Year [2024]	USD 218.99 million
Forecast Year [2030]	USD 290.85 million
CAGR (%)	4.81%

Form: Suitability of auranofin capsules to provide a systemic delivery of the active drug, ensuring a uniform distribution

Auranofin in capsule form is a recognized oral treatment option primarily designed for the management of rheumatoid arthritis. The convenience of capsule administration makes it suitable for patients who may have difficulty with other forms of medication. Auranofin capsules provide a systemic delivery of the active drug, ensuring a uniform distribution throughout the body. This form is particularly noted for its effectiveness in reducing inflammation, improving joint mobility, and decreasing pain with a dosage and administration schedule that is optimized for patient compliance and therapeutic efficacy. The tablet form of auranofin offers a tailored approach to the treatment of rheumatoid arthritis, combining ease of use with precise dosage control. Tablets are highly favored for their portability, stability, and ability to incorporate controlled-release formulations, which can improve the pharmacokinetic profile of auranofin. This means a more consistent drug level in the body over time, potentially leading to improved patient outcomes and reduced side effects. The tablet form can also facilitate adherence to treatment schedules, an important factor in the long-term management of chronic conditions.

Indication: Preference for auranofin in managing seropositive RA owing to its cellular mechanisms involved in inflammation.

Seronegative rheumatoid arthritis (RA) refers to a subtype of rheumatoid arthritis where the blood of the patient does not contain rheumatoid factor (RF) or anti-cyclic citrullinated peptide (anti-CCP) antibodies, which are typically found in rheumatoid arthritis patients. Despite the absence of these antibodies, seronegative RA can still cause significant joint inflammation and damage. Auranofin, an oral gold compound, has been utilized in the management of seronegative RA for its anti-inflammatory properties. It functions by modulating the immune system, thus reducing the inflammation and progression of the disease. Treatment approaches with auranofin in seronegative RA emphasize controlling symptoms and preventing joint damage, acknowledging the challenges in diagnosing and managing this subtype due to the lack of specific biomarkers. Seropositive Rheumatoid Arthritis is characterized by the presence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) antibodies in the patient's blood. This form of RA is often associated with a more aggressive disease course, including more significant joint damage and a higher risk of developing extra-articular manifestations. Auranofin's role in managing seropositive RA has been recognized due to its capacity to inhibit cellular mechanisms involved in inflammation. By targeting specific pathways that lead to the production of pro-inflammatory cytokines, auranofin helps in reducing inflammation, swelling, and pain in affected joints. Although it is not among the first-line treatments for RA, Auranofin presents a therapeutic option for patients intolerant or unresponsive to conventional disease-modifying antirheumatic drugs (DMARDs) or biologic agents, aiming to reduce disease activity & improve the quality of life of patients with seropositive RA.

Regional Insights

In the Americas, particularly in the United States and Canada, the market for auranofin has been driven by its prolonged use in treating chronic rheumatoid arthritis. The market is mature with a stable demand, largely due to the established healthcare infrastructure and reimbursement policies favoring the drug's prescription. However, growing competition from newer biologic DMARDs and biosimilars poses challenges to its market share. In Europe, the market is highly regulated with a strong emphasis on cost-effectiveness and clinical outcomes, which could limit the growth potential of Auranofin despite its proven efficacy. The Middle East, while smaller in market size, shows promise due to growing healthcare infrastructure and investment. The Asia Pacific region is anticipated to depict significant growth for the auranofin market due to rapidly evolving healthcare systems, increasing patient awareness, and growing prevalence of rheumatoid arthritis. Countries including China and India, with their vast populations and improving healthcare settings, are expected to contribute substantially to the market. Furthermore, the region's increasing research and development activities may offer new opportunities for Auranofin in alternative therapeutic applications.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Auranofin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Auranofin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Auranofin Market, highlighting leading vendors and their innovative profiles. These include Chugai Pharmaceutical Co Ltd, LGM Pharma, Prometheus Laboratories Inc., Sebela Pharmaceuticals Inc., Taj Pharmaceuticals Limited, and Xediton Pharmaceuticals.

Market Segmentation & Coverage

This research report categorizes the Auranofin Market to forecast the revenues and analyze trends in each of the following sub-markets:

Form
- Capsule
- Tablet

Indication
- Seronegative Rheumatoid Arthritis
- Seropositive Rheumatoid Arthritis

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Auranofin Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Auranofin Market?

3. What are the technology trends and regulatory frameworks in the Auranofin Market?

4. What is the market share of the leading vendors in the Auranofin Market?

5. Which modes and strategic moves are suitable for entering the Auranofin Market?

Product Code: MRR-F97DD5A7D98B

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of rheumatoid arthritis and the need for alternative treatments
  - 5.1.1.2. Auranofin's potential against parasitic infections, certain cancers, and as an antiviral agent.
  - 5.1.1.3. Governmental and non-governmental funding for chronic diseases and cancer research
- 5.1.2. Restraints
  - 5.1.2.1. Side effects associated with Auranofin
- 5.1.3. Opportunities
  - 5.1.3.1. Exploring auranofin's efficacy in new therapeutic applications
  - 5.1.3.2. Partnerships between pharmaceutical companies and research institutions
- 5.1.4. Challenges
  - 5.1.4.1. Complex regulatory landscape and the high cost of clinical trials
5.2. Market Segmentation Analysis
- 5.2.1. Form: Suitability of auranofin capsules to provide a systemic delivery of the active drug, ensuring a uniform distribution
- 5.2.2. Indication: Preference for auranofin in managing seropositive RA owing to its cellular mechanisms involved in inflammation.
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Auranofin Market, by Form

6.1. Introduction
6.2. Capsule
6.3. Tablet

7. Auranofin Market, by Indication

7.1. Introduction
7.2. Seronegative Rheumatoid Arthritis
7.3. Seropositive Rheumatoid Arthritis

8. Americas Auranofin Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Auranofin Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Auranofin Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
- 11.3.1. Arthritis Foundation Invests USD 1.1 Million in Refractory Rheumatoid Arthritis Research
11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

12.1. Key Company Profiles
12.2. Key Product Portfolio